Abstract: A dosage-indicating topical formulation and a method of using said formulation is described. The topical formulation includes one or more bioactive substances and a topical dosage indicator. The topical dosage indicator includes one or more colored copper-containing compounds, and has a color that changes as the topical dosage indicator is absorbed into the skin. The copper-containing compound may include, for example, a copper (II) salt or a copper (I) salt; and a complexation agent containing donor atoms acting as ligands, where the donor atoms are selected from the group consisting of one or more of a nitrogen (N) atom, an oxygen (O) atom, a sulfur (S) atom. The method of using the dosage indicating topical formulation includes repeated rubbing portions of the topical formulation into the skin until the change in color indicates that the skin is saturated with the formulation.

Abstract: The present invention relates to monospecific antibodies against CXCR4 or binding fragments thereof, to the use of such anti-CXCR4 antibodies or binding fragments in treating diseases whose pathogenesis is related to activation of CXCR4, as well as to pharmaceutical compositions comprising such anti-CXCR4 antibodies or binding fragments.

Abstract: Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR7 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR7 receptor, including cancers. Other uses include detection of human CCR7 receptor in biological samples for diagnostic or evaluative purposes. Fully human antibodies against human CCR7 therefore can be used to diagnose disorders involving CCR7. Further, antibodies of this invention can be useful for treating disorders involving CCR7 by inhibiting binding of native chemokines to the CCR7, and thereby decrease effects of those chemokines. Anti-CCR7 antibodies of this invention can also be used as specific targeting agents to bring toxic agents to CCR7-expressing cells, to inhibit chemotaxis, and therefore can be effective therapeutic agents.